Endoscopic Retrograde Cholangiopancreatography Market Size Report, 2022-2030
The global Endoscopic Retrograde Cholangiopancreatography market size was estimated at USD 1.9 billion in 2022 and is expected to surpass around USD 4.0 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 11.6% during the forecast period 2022 to 2030. The drivers of the market include the rising incidence of cancer, increasing investments by governments and healthcare organizations to improve endoscopy research, growing focus on investments by hospitals for advanced endoscopy instruments, and the increasing preference for minimally invasive surgeries.
Covid-19 Impact on the Endoscopic retrograde cholangiopancreatography Market
The COVID-19 pandemic has resulted in a global crisis. Surgeons and patients visiting hospitals for various treatments are at increased risk of getting infected by COVID-19. Most of the gastrointestinal procedures were suspended, leading to a decrease in device-based treatments such as ERCP. Around 40–50% of endoscopy procedures were canceled in major hospitals across Germany. According to a research study, the COVID-19 pandemic significantly reduced ERCP procedures. The success rate was also lowered due to restrictions on endoscopic services in the UK and worldwide. This negatively impacted the ERCP market. Moreover, endoscopy is considered an aerosol-generating procedure, which imposes the risk of transmission to health care professionals. Nevertheless, the providers use PPE kits and further precaution measures to continue endoscopy procedures.
The sales of disposable endoscopes have risen in contrast to autoclavable endoscopes as many hospitals and clinics lack the resources and manpower to adhere to and implement the stringent COVID-19 guidelines put forth by the European Society for Gastrointestinal Endoscopy (ESGE) and the German Respiratory Society (Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin or DGP). The use of negative pressure suites and personal protective kits and spatial separation of wards are recommended to avoid the risk of infection. Additionally, a research study revealed that the use of Enhanced Personal Protective Equipment (EPPE) had no negative effects on ERCP performance in this patient group.
Report Scope of the Endoscopic Retrograde Cholangiopancreatography Market
|
Report Coverage |
Details |
|
Market Size |
US$ 4.0 Billion by 2030 |
|
Growth Rate |
CAGR of 11.6% from 2022 to 2030 |
|
Largest Market |
North America |
|
Fastest Growing Market |
Asia Pacific |
|
Base Year |
2021 |
|
Forecast Period |
2022 to 2030 |
|
Segments Covered |
Product, procedure, end-user, andand Region, |
|
Companies Mentioned |
Olympus Corporation (Japan), CONMED Corporation (US), Fujifilm Holdings Corporation (Japan), HOYA Corporation (Japan), KARL STORZ SE & Co. KG (Germany), Ambu A/S (Denmark), Boston Scientific Corporation (US), Johnson & Johnson (US), Medtronic, PLC (Ireland), Cook Medical (US), and B. Braun Melsungen AG (Germany). |
Endoscopic retrograde cholangiopancreatography Market Dynamics
Driver: Rising incidence of cancer
Nowadays, the global incidence of cancer is increasing. According to the WHO, cancer is the second-leading cause of death globally and was responsible for 9.6 million deaths in 2018. According to the American Cancer Society’s estimates, about 41,260 new cases of liver cancer and intrahepatic bile duct cancer will be diagnosed in 2022 in the US. Liver cancer incidence rates have more than tripled since 1980, while the death rates have more than doubled during this time. In 2021, around 60,430 new pancreatic cases were diagnosed in the US. In the UK (2016-2018), around 10,500 new pancreatic cancer cases and 6,200 liver cancer cases every year. Globally, 458,918 new cases of pancreatic cancer were reported in 2018, and 355,317 new cases are estimated to occur until 2040 (GLOBOCAN 2018 estimates).
Since ERCP is often used as a diagnostic tool in hepatic, bile duct, and pancreatic cancers, the rising incidence of these cancers is directly related to the impact on the ERCP market
Restraint: High costs of endoscopic retrograde cholangiopancreatography devices
One of the most pertinent restraining factors for the market is the high costs of ERCP equipment and procedures. The average selling price of a duodenoscope is around USD 31,500 (Non- HD) to USD 37,000 (HD). This high price, combined with the long procedure time, makes this unfavorable. Additionally, an interview conducted with an expert in the ERCP market cost can be one of the leading reasons for the procedure not being easily accessible and affordable to many small-scale end users, which cater to a large population, especially in developing countries.
Opportunity: The growing healthcare sector in emerging economies
Brazil, Russia, India, China, and South Africa (BRICS) are among the fastest-growing economies globally. According to World Economic Forum, the emerging economies accounted for around one-third of the global healthcare expenditure in 2021. More than half of the world’s population resides in India and China, owing to which these countries are home to the highest number of patients.
The increasing burden of cancer, rapid improvements in healthcare infrastructure, the rapid growth of medical tourism, and the presence of flexible regulation in these countries encourage players in the endoscopy equipment market to expand their presence in emerging countries.
Several endoscopy equipment manufacturers are currently setting up their facilities in the Asia Pacific, the Middle East, and Latin America. Key players such as KARL STORZ have already set up their manufacturing and R&D facilities in these countries. In addition, market saturation in developed regions, such as North America and Europe, will compel manufacturers to focus on emerging markets in the coming years.
These factors are expected to offer significant growth opportunities for the ERCP market.
Asia-Pacific and Latin America are the fastest-growing markets for endoscopic retrograde cholangiopancreatography market during the forecast period.
Governments in several Latin American countries focus on improving their respective healthcare systems, and the healthcare sector in Brazil has undergone significant changes, making the country one of the world's most promising and attractive markets. Along with this, Japan’s well-developed healthcare system with universal health insurance coverage, and the focus of countries such as China and India on healthcare infrastructure improvements to serve large populations of patients with critical illnesses, including cancer, and tumors are driving the market in these regions forward at a rapid pace.
Some of the prominent players in the Endoscopic Retrograde Cholangiopancreatography Market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Endoscopic Retrograde Cholangiopancreatography market
Product
Procedure
End User
By Geography
North America
Europe
Asia Pacific
Latin America
Middle East & Africa (MEA)
Key Points Covered in Endoscopic Retrograde Cholangiopancreatography Market Study:
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers